MCID: CRB138
MIFTS: 47

Core Binding Factor Acute Myeloid Leukemia malady

Category: Cancer diseases

Aliases & Classifications for Core Binding Factor Acute Myeloid Leukemia

About this section

Aliases & Descriptions for Core Binding Factor Acute Myeloid Leukemia:

Name: Core Binding Factor Acute Myeloid Leukemia 23 65
Cbf Acute Myeloid Leukemia 23
 
Core-Binding Factor Aml 23
Cbf-Aml 23

Classifications:



External Ids:

UMLS65 C3839741

Summaries for Core Binding Factor Acute Myeloid Leukemia

About this section
Genetics Home Reference:23 Core binding factor acute myeloid leukemia (CBF-AML) is one form of a cancer of the blood-forming tissue (bone marrow) called acute myeloid leukemia. In normal bone marrow, early blood cells called hematopoietic stem cells develop into several types of blood cells: white blood cells (leukocytes) that protect the body from infection, red blood cells (erythrocytes) that carry oxygen, and platelets (thrombocytes) that are involved in blood clotting. In acute myeloid leukemia, the bone marrow makes large numbers of abnormal, immature white blood cells called myeloid blasts. Instead of developing into normal white blood cells, the myeloid blasts develop into cancerous leukemia cells. The large number of abnormal cells in the bone marrow interferes with the production of functional white blood cells, red blood cells, and platelets.

MalaCards based summary: Core Binding Factor Acute Myeloid Leukemia, also known as cbf acute myeloid leukemia, is related to hematopoietic stem cell transplantation and leukemia. An important gene associated with Core Binding Factor Acute Myeloid Leukemia is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways are Agrin Interactions at Neuromuscular Junction and EGFR Transactivation by Gastrin. Affiliated tissues include myeloid, bone and bone marrow, and related mouse phenotypes are pigmentation and respiratory system.

Related Diseases for Core Binding Factor Acute Myeloid Leukemia

About this section

Diseases related to Core Binding Factor Acute Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 93)
idRelated DiseaseScoreTop Affiliating Genes
1hematopoietic stem cell transplantation28.4CSF3, FLT3, HRAS, JAK2, KIT, RUNX1
2leukemia10.9
3myeloid leukemia10.9
4acute myeloid leukemia, kit-related10.7FLT3, KIT
5acute myeloblastic leukemia without maturation10.7FLT3, KIT
6alg1-congenital disorder of glycosylation10.5FLT3, RUNX1
7acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor10.5FLT3, KIT, RUNX1
8brachydactyly, type e210.5KRAS, NRAS
9hepatic osteogenic sarcoma10.5KIT, NRAS
10lung sarcoma10.5KRAS, NRAS
11osteogenesis imperfecta-retinopathy-seizures-intellectual disability syndrome10.4FLT3, KIT
12intracystic papillary adenoma10.4HRAS, KRAS
13bile duct cystadenocarcinoma10.4KRAS, NRAS
14melanocytic nevus syndrome, congenital, somatic10.4HRAS, NRAS
15sublingual gland adenoid cystic carcinoma10.4KIT, NRAS
16gastrointestinal carcinoma10.4KRAS, NRAS
17apocrine adenocarcinoma10.4HRAS, KRAS
18lacrimal passage granuloma10.3KIT, KRAS, NRAS
19classic hodgkin lymphoma, mixed cellularity type10.3FLT3, JAK2, RUNX1
20thrombocythemia 310.3FLT3, JAK2, KIT
21benign mesenchymoma10.3KRAS, NRAS
22chronic myocardial ischemia10.3FLT3, JAK2, RUNX1
23hypervitaminosis d10.3CSF1R, KIT
24adult central nervous system teratoma10.3FLT3, RUNX1
25neonatal stroke10.3FLT3, JAK2, KIT
26tetrasomy 12p10.2HRAS, KRAS, NRAS
27sigmoid disease10.2HRAS, KRAS, NRAS
28diabetic encephalopathy10.2HRAS, KRAS, NRAS
29epidermal nevus, somatic10.2HRAS, KRAS, NRAS
30chronic inflammatory demyelinating polyradiculoneuropathy10.2HRAS, KRAS, NRAS
31schimmelpenning-feuerstein-mims syndrome, somatic mosaic10.2HRAS, KRAS, NRAS
32erythrasma10.2HRAS, KRAS, NRAS
33precursor lymphoblastic lymphoma/leukemia10.2HRAS, KRAS, NRAS
34ovarian serous cystadenocarcinoma10.2HRAS, KRAS, NRAS
35neuromuscular disease10.2HRAS, KRAS, NRAS
36anterior horn cell disease10.2HRAS, KRAS, NRAS
37ovarian mucinous adenocarcinoma10.2HRAS, KRAS, NRAS
38migraine with aura10.2HRAS, KRAS, NRAS
39malignant giant cell tumor of soft parts10.2HRAS, KRAS, NRAS
40pneumonic plague10.2HRAS, KRAS, NRAS
41small intestine leiomyoma10.2HRAS, KRAS, NRAS
42serous surface papilloma10.2HRAS, KRAS, NRAS
43osteoclast-like giant cell neoplasm of the pancreas10.2HRAS, KRAS, NRAS
44mucinous stomach adenocarcinoma10.2HRAS, KRAS, NRAS
45biliary tract intraductal papillary mucinous neoplasm10.2HRAS, KRAS, NRAS
46congenital structural myopathy10.1HRAS, KRAS, NRAS
47cavernous hemangioma10.1HRAS, KRAS, NRAS
48bile duct carcinoma10.1HRAS, KRAS, NRAS
49bacterial exanthem10.1HRAS, KRAS, NRAS
50biliary tract neoplasm10.1HRAS, KRAS, NRAS

Graphical network of the top 20 diseases related to Core Binding Factor Acute Myeloid Leukemia:



Diseases related to core binding factor acute myeloid leukemia

Symptoms for Core Binding Factor Acute Myeloid Leukemia

About this section

Drugs & Therapeutics for Core Binding Factor Acute Myeloid Leukemia

About this section

Drugs for Core Binding Factor Acute Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Dasatinibapproved, investigationalPhase 3, Phase 2, Phase 1268302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anh. dasatinib
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
 
Dasatinibum
EC-000.2122
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
dasatinib
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
2
Cytarabineapproved, investigationalPhase 3, Phase 1, Phase 21035147-94-46253
Synonyms:
(beta-D-Arabinofuranosyl)cytosine
(beta-D-arabinofuranosyl)cytosine
1-.beta.-D-arabinofuranosyl-cytosine
1-Arabinofuranosylcytosine
1-beta -D-Arabinofaranosylcytosine
1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta -D-Arabinofuranosylcytosine
1-beta-D-Arabinofaranosylcytosine
1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1-beta-D-Arabinofuranosyl-Cytosine
1-beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside
1-beta-D-Arabinosyl-Cytosine
1-beta-D-Arabinosylcytosine
147-94-4
1beta -Arabinofuranasylcytosine
1beta -D-Arabinofuranosylcytosine
1beta -D-Arabinosylcytosine
1beta-Arabinofuranasylcytosine
1beta-D-Arabinofuranosylcytosine
1beta-D-Arabinosylcytosine
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl- [CAS]
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl
30399_FLUKA
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
69-74-9 (hydrochloride)
AC-1075
AC1L1M4F
AC1Q52OJ
AI3-52329
AR3
Alexan
Ara-C
Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine
Ara-Cytidine
AraC
Arabinocytidine
Arabinofuranosyl Cytidine
Arabinofuranosylcytosine
Arabinosyl Cytosine
Arabinosylcytosine
Arabitin
Aracytidine
Aracytin
Aracytine
Arafcyt
BIDD:GT0371
BIDD:PXR0139
BTB15125
Beta-cytosine arabinoside
C02961
C1768_SIGMA
C2035
C9H13N3O5
CCRIS 913
CHEBI:28680
CHEMBL803
CHX 3311
CID6253
CPD000449317
CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9)
Citarabina
Citarabina [INN-Spanish]
Cytarabin
Cytarabina
Cytarabine
Cytarabine (JP15/USP/INN)
 
Cytarabine [USAN:INN:BAN:JAN]
Cytarabine liposome injection
Cytarabinoside
Cytarabinum
Cytarabinum [INN-Latin]
Cytarbel
Cytonal
Cytosar
Cytosar-U
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine arabinoside (VAN)
Cytosine beta-D-arabinofuranoside
Cytosine beta-D-arabinofuranoside hydrochloride
Cytosine beta-D-arabinoside
Cytosine, beta -D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside hydrochloride
Cytosine-beta -D-arabinofuranoside
Cytosine-beta -arabinoside
Cytosine-beta-D-arabinofuranoside
Cytosine-beta-arabinoside
Cytosinearabinoside
D00168
DB00987
DepoCyte
Depocyt
Depocyt (TN)
Depocyt (liposomal)
Depocyte
EINECS 205-705-9
Erpalfa
FT-0082880
HMS2051K19
HMS2090A18
HSDB 3049
Intrathecal (injected into the spinal fluid) DepoCyt
Intrathecal cytarabine (also known as ara-C)
Iretin
LS-860
Lopac0_000316
MLS000758310
MLS001066340
MolPort-001-792-509
NCGC00093356-03
NCGC00093356-04
NCGC00093356-05
NCI-C04728
NSC 287459
NSC287459
S1648_Selleck
SAM001247012
SMR000449317
SR-01000075773-3
Spongocytidine
TL8001048
Tarabine
U 19920A
U-19,920
U-19920
UNII-04079A1RDZ
Udicil
ZINC03795098
beta -D-arabinosylcytosine
beta -arabinosylcytosine
beta -cytosine arabinoside
beta-Ara C
beta-Ara c
beta-Arabinosylcytosine
beta-Cytosine arabinoside
beta-D-Arabinosylcytosine
cytarabine
cytarabine liposome injection
cytosine-β-D-arabinofuranoside
3
DaunorubicinapprovedPhase 3, Phase 1, Phase 225220830-81-330323
Synonyms:
(+)-Daunomycin
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
(8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione
(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro--6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione
11006-54-5
11048-29-6
1407-15-4
149541-57-1
20830-81-3
23942-76-9
27576-81-4
28020-80-6
AB00514669
AC1L1JCP
AC1Q29OI
AI3-52942
Acetyladriamycin
Anthracyline
Antibiotics From Streptomyces Coeruleorubidus
Antibiotics from Streptomyces coeruleorubidus
BPBio1_000389
BRD-K43389675-003-02-7
BRN 1445583
BSPBio_000353
C01907
CCRIS 914
CHEBI:41977
CHEMBL178
CID30323
Cerubidin
Cerubidine
D07776
DAUNORUBICIN HCL
DB00694
DM1
Daunamycin
Daunarubicinum
Dauno-Rubidomycine
DaunoXome
DaunoXome (TN)
Daunoblastin
Daunoblastine
Daunomycin
 
Daunomycin Hydrochloride
Daunomycin, Hydrochloride
Daunorrubicina
Daunorubicin
Daunorubicin (INN)
Daunorubicin (liposomal)
Daunorubicin Hcl
Daunorubicin Hydrochloride
Daunorubicin [INN:BAN]
Daunorubicin, Hydrochloride
Daunorubicina
Daunorubicine
Daunorubicinum
Daunorubicinum [INN-Latin]
Daunoxome
EINECS 244-069-7
FI 6339
FI6339
HMS2089H04
HMS2091K06
HSDB 5095
LMPK13050002
LS-187381
LS-997
Leukaemomycin C
MolPort-002-533-961
NCGC00024246-05
NCGC00024246-06
NCGC00025173-01
NCI-C04693
NChemBio.2007.10-comp14
NSC 83142
NSC-82151
Ondena
Prestwick3_000487
RCRA waste no. U059
RP 13057
Rcra Waste No. U059
Rp 13057 Hydrochloride
Rubidomycin
Rubidomycin Hydrochloride
Rubomycin
Rubomycin C
Tocris-1467
UNII-ZS7284E0ZP
VS-103
daunorubicin
nchembio723-comp2
4Antibiotics, AntitubercularPhase 3, Phase 1, Phase 25971
5Anti-Infective AgentsPhase 3, Phase 1, Phase 217220
6Protein Kinase InhibitorsPhase 3, Phase 2, Phase 13162
7Anti-Bacterial AgentsPhase 3, Phase 1, Phase 29140
8Topoisomerase InhibitorsPhase 3, Phase 1, Phase 24081
9AntimetabolitesPhase 3, Phase 1, Phase 29454
10Immunosuppressive AgentsPhase 3, Phase 1, Phase 210422
11Antimetabolites, AntineoplasticPhase 3, Phase 1, Phase 25770
12Antiviral AgentsPhase 3, Phase 1, Phase 28071
13Immunologic FactorsPhase 3, Phase 1, Phase 218483
14
Mitoxantroneapproved, investigationalPhase 225765271-80-94212
Synonyms:
1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE
1,4-DIHYDROXY-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthracenedione
1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione
1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon
1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione
137635-96-2
2fum
5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone
65271-80-9
70476-82-3
70476-82-3 (hydrochloride)
70711-41-0
70711-41-0 (acetate)
70945-62-9
9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- (9CI)
AB00053716
AC1L1HNY
AN-584/42007670
BIDD:PXR0181
BPBio1_000627
BRD-K21680192-300-05-2
BRD-K21680192-300-07-8
BRN 2795126
BSPBio_000569
BSPBio_003160
C11195
C22H28N4O6
CAS-70476-82-3
CCRIS 7604
CHEBI:50729
CHEMBL58
CID4212
D08224
DB01204
DHAD
DHAQ
DHAQ (*Diacetate salt*)
DHAQ HCl
Dihydroxyanthraquinone
DivK1c_000516
HMS2090D05
IDI1_000516
KBio1_000516
KBio2_002135
KBio2_004703
KBio2_007271
KBio3_002660
KBioGR_001531
KBioSS_002135
LS-20638
Liposome Encapsulated Mitoxantrone (LEM)
Lopac-M-6545
Lopac0_000779
MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE
MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE
MIX
MLS002703044
 
Misostol
Misostol (TN)
Mitox
Mitoxanthrone
Mitoxantron
Mitoxantrona
Mitoxantrona [INN-Spanish]
Mitoxantrone
Mitoxantrone (INN)
Mitoxantrone (free base)
Mitoxantrone 2HCl
Mitoxantrone HCl
Mitoxantrone Hydrochloride
Mitoxantrone [INN]
Mitoxantrone dihydrochloride
Mitoxantrone hydrochloride
Mitoxantronum
Mitoxantronum [INN-Latin]
Mitozantrone
Mitozantrone hydrochloride
MolPort-003-849-239
NCGC00015693-01
NCGC00015693-02
NCGC00015693-04
NCGC00162251-01
NCI60_002276
NCI60_002535
NChemBio.2007.10-comp17
NINDS_000516
NSC 279836
NSC-279836
NSC-287836
NSC-299195
NSC-301739
NSC-301739D
NSC279836
NSC299195
NSC301739
Neuro_000153
Novantron
Novantrone
Novantrone(R) (mitoxantrone for injection concentrate)
Prestwick0_000385
Prestwick1_000385
Prestwick2_000385
Prestwick3_000385
S2485_Selleck
SMP2_000179
SMR001549953
SPBio_000756
SPBio_002490
SR-01000076001
SR-01000076001-7
STK631833
Spectrum2_000908
Spectrum3_001590
Spectrum4_000866
Spectrum5_001205
Spectrum_001655
UNII-BZ114NVM5P
VU0244399-2
mitoxantrone
15
EtoposideapprovedPhase 2116933419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
 
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide Phosphate
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
16
Busulfanapproved, investigationalPhase 250655-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
17
IdarubicinapprovedPhase 2, Phase 119958957-92-942890
Synonyms:
(1S,3S)-3-Acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-|A-l-lyxo-hexopyranoside
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
(7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione
4-DMD
4-Demethoxydaunomycin
4-Demethoxydaunorubicin
4-Desmethoxydaunorubicin
57852-57-0
57852-57-0 (HYDROCHLORIDE)
58957-92-9
AC1L28SA
AC1Q6JJ4
BRD-K69650333-001-01-1
C26H27NO9
CCRIS 5083
CHEBI:42068
CHEMBL1117
CID42890
D08062
DB01177
DM5
DMDR
EU-0100600
HMS2089D05
I 1656
I06-1097
I1656_SIGMA
IDARUBICIN
IMI 30
 
IMI-30
Idamycin
Idamycin PFS
Idarubicin
Idarubicin (INN)
Idarubicin Aglycone
Idarubicin HCl PFS
Idarubicin Hcl
Idarubicin Hcl Pfs
Idarubicin Hydrochloride
Idarubicin [INN:BAN]
Idarubicina
Idarubicina [INN-Spanish]
Idarubicine
Idarubicine [INN-French]
Idarubicinum
Idarubicinum [INN-Latin]
KBioSS_002388
LS-94015
Lopac0_000600
MLS000759470
NCGC00093976-01
NCGC00093976-02
NCGC00093976-03
NCGC00093976-04
NSC-256439
NSC256439
SMR000466355
UNII-ZRP63D75JW
Zavedos
Zavedos (TN)
idarubicin hydrochloride
18
FludarabineapprovedPhase 2, Phase 1105921679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-Fluoro-ara AMP
2-Fluoroadenine arabinoside 5'-monophosphate
21679-14-1
2F-Ara-AMP
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
 
Fludara, Fludarabine
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine Phosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
Oforta
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
19
Flavopiridolexperimental, investigationalPhase 260131740-09-55287969
Synonyms:
(-)cis-5,7-Dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one
131740-09-5
146426-40-6
1c8k
1e1y
2-(2-CHLORO-PHENYL)-5,7-DIHYDROXY-8-(3-HYDROXY-1-METHYL-PIPERIDIN-4-YL)-4H-BENZOPYRAN-4-ONE
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one
358739-39-6
AC1NRALK
Alvocidib
Alvocidib [INN]
C21H20ClNO5
CHEMBL428690
CHEMBL8817
CID5287969
 
DB03496
FLAVO
Flavopiridol
Flavopiridol hydrochloride
HMR-1275
HMR-1275, Alvocidib, L868275, Flavopiridol
L 868275
L-868275
L86-8275
L868275
LS-173272
NSC649890
S1230_Selleck
UNII-45AD6X575G
alvocidib
flavopiridol
20Peripheral Nervous System AgentsPhase 218510
21AnalgesicsPhase 29358
22Fludarabine phosphatePhase 2, Phase 1105930751
23Etoposide phosphatePhase 21169
24Adjuvants, ImmunologicPhase 21783
25lenograstimPhase 21134

Interventional clinical trials:

(show all 11)
idNameStatusNCT IDPhase
1Timed-Sequential Induction in CBF-AMLCompletedNCT00428558Phase 3
2Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)RecruitingNCT02013648Phase 3
3Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous LeukemiaCompletedNCT02113319Phase 2
4Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)CompletedNCT00850382Phase 1, Phase 2
5Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00407966Phase 2
6Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid LeukemiaRecruitingNCT01050036Phase 2
7Autologous Hematopoietic Cell Transplantation for Core-binding Factor (CBF) Acute Myeloid Leukemia (AML) in the First Complete Remission (CR1)RecruitingNCT01146977Phase 2
8Fludarabine, Cytarabine, Filgrastim and Idarubicin in Core Binding Factor (CBF) LeukemiasRecruitingNCT00801489Phase 2
9Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT01238211Phase 2
10Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid LeukemiaRecruitingNCT02680951Phase 1
11Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid LeukemiaRecruitingNCT01066286

Search NIH Clinical Center for Core Binding Factor Acute Myeloid Leukemia

Genetic Tests for Core Binding Factor Acute Myeloid Leukemia

About this section

Anatomical Context for Core Binding Factor Acute Myeloid Leukemia

About this section

MalaCards organs/tissues related to Core Binding Factor Acute Myeloid Leukemia:

33
Myeloid, Bone, Bone marrow, Prostate, Kidney, Monocytes, Endothelial

Animal Models for Core Binding Factor Acute Myeloid Leukemia or affiliated genes

About this section

MGI Mouse Phenotypes related to Core Binding Factor Acute Myeloid Leukemia:

38 (show all 24)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.5CBL, KIT, KRAS, NRAS
2MP:00053888.5CBFB, CBL, HRAS, KIT, KRAS, RUNX1
3MP:00020068.3CBFB, FLT3, HRAS, JAK2, KIT, KRAS
4MP:00030128.3CBFB, FLT3, HRAS, KIT, KRAS, NRAS
5MP:00053718.2CBFB, CBL, CSF1R, KIT, KRAS, NRAS
6MP:00053708.2CBFB, CBL, JAK2, KIT, KRAS, NRAS
7MP:00028738.0CBFB, CSF1R, HRAS, JAK2, KIT, KRAS
8MP:00053857.9CBFB, CBL, HRAS, KIT, KRAS, NRAS
9MP:00053827.7CBFB, CBL, CSF1R, HRAS, KIT, KRAS
10MP:00053847.2CBFB, CBL, CSF1R, FLT3, JAK2, KIT
11MP:00053796.8CBFB, CBL, CSF1R, FLT3, HRAS, JAK2
12MP:00053906.8CBFB, CBL, CSF1R, FLT3, HRAS, JAK2
13MP:00053766.7CBFB, CBL, CSF1R, FLT3, HRAS, JAK2
14MP:00107686.7CBFB, CBL, CSF1R, FLT3, HRAS, JAK2
15MP:00053786.7CBFB, CBL, CSF1R, FLT3, HRAS, JAK2
16MP:00107716.3CBFB, CBL, CSF1R, CSF3, HRAS, JAK2
17MP:00053876.1CBFB, CBL, CSF1R, CSF3, FLT3, JAK2
18MP:00053976.1CBFB, CBL, CSF1R, CSF3, FLT3, JAK2

Publications for Core Binding Factor Acute Myeloid Leukemia

About this section

Articles related to Core Binding Factor Acute Myeloid Leukemia:

(show top 50)    (show all 53)
idTitleAuthorsYear
1
Stem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia. (26880987)
2016
2
Comprehensive mutational profiling of core binding factor acute myeloid leukemia. (26980726)
2016
3
Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia. (26771813)
2016
4
Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population. (25932436)
2015
5
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up. (25753065)
2015
6
Additional chromosomal abnormalities in core-binding factor acute myeloid leukemia. (26681050)
2015
7
Core Binding Factor Acute Myeloid Leukemia: New Prognostic Categories and Therapeutic Opportunities. (26111469)
2015
8
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission. A French Acute Myeloid leukemia Intergroup trial. (25715404)
2015
9
Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. (25348871)
2014
10
Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. (24793731)
2014
11
Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy. (25088818)
2014
12
Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center. (25449688)
2014
13
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. (25006122)
2014
14
High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML). (24844781)
2014
15
Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia. (24972769)
2014
16
The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia. (23783394)
2013
17
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement. (23053179)
2013
18
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. (23321257)
2013
19
Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children. (23677335)
2013
20
Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? (24319183)
2013
21
Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results. (23266036)
2013
22
Prognosis of patients with core binding factor acute myeloid leukemia after first relapse. (23716553)
2013
23
Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease. (23646898)
2013
24
Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia. (22145956)
2012
25
High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. (22234698)
2012
26
Impact of residual normal metaphases in core binding factor acute myeloid leukemia. (21928314)
2012
27
A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia. (22886749)
2012
28
Treatment strategies in patients with core-binding factor acute myeloid leukemia. (21755276)
2011
29
Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. (21715005)
2011
30
Core binding factor acute myeloid leukemia (CBF-AML) in MAcxico: a single institution experience. (21574542)
2011
31
Core-binding factor acute myeloid leukemia. (22032582)
2011
32
Peripheral blasts on day 21 of induction chemotherapy in a patient with core binding factor acute myeloid leukemia: more than meets the eye. (20709669)
2010
33
Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think? (19468270)
2009
34
Rapid detection of KIT mutations in core-binding factor acute myeloid leukemia using high-resolution melting analysis. (19644024)
2009
35
Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. (19126873)
2009
36
Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome. (19603346)
2009
37
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. (18981008)
2008
38
Core binding factor acute myeloid leukemia. (18692691)
2008
39
A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. (18297529)
2008
40
Autologous stem cell transplantation with PCR-negative graft would be associated with a favorable outcome in core-binding factor acute myeloid leukemia. (18940681)
2008
41
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. (18841055)
2008
42
Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. (17960171)
2008
43
Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. (17485551)
2007
44
Core binding factor acute myeloid leukemia. (16728942)
2006
45
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). (16598313)
2006
46
Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. (16015387)
2005
47
Expression of the neural cell adhesion molecule CD56 is not associated with P-glycoprotein overexpression in core-binding factor acute myeloid leukemia. (15068897)
2004
48
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. (15289486)
2004
49
Core binding factor acute myeloid leukemia. Cancer and Leukemia Group B (CALGB) Study 8461. (15124687)
2004
50
Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts. (14695213)
2003

Variations for Core Binding Factor Acute Myeloid Leukemia

About this section

Expression for genes affiliated with Core Binding Factor Acute Myeloid Leukemia

About this section
Search GEO for disease gene expression data for Core Binding Factor Acute Myeloid Leukemia.

Pathways for genes affiliated with Core Binding Factor Acute Myeloid Leukemia

About this section

Pathways related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

(show top 50)    (show all 82)
idSuper pathwaysScoreTop Affiliating Genes
19.3HRAS, KRAS, NRAS
2
Show member pathways
9.3HRAS, KRAS, NRAS
39.3HRAS, KRAS, NRAS
49.3HRAS, KRAS, NRAS
59.3HRAS, KRAS, NRAS
69.3HRAS, KRAS, NRAS
79.3HRAS, KRAS, NRAS
89.3HRAS, KRAS, NRAS
99.3HRAS, KRAS, NRAS
109.3HRAS, KRAS, NRAS
119.3HRAS, KRAS, NRAS
129.3HRAS, JAK2, RUNX2
139.2JAK2, RUNX2, TLE1
14
Show member pathways
9.1HRAS, KIT, KRAS, NRAS
159.0CSF1R, FLT3, KIT, RUNX2
169.0HRAS, JAK2, KRAS, NRAS
17
Show member pathways
9.0HRAS, JAK2, KRAS, NRAS
189.0HRAS, JAK2, KRAS, NRAS
19
Show member pathways
9.0HRAS, JAK2, KRAS, NRAS
208.9CSF1R, FLT3, RUNX1, RUNX2
21
Show member pathways
8.9CBL, HRAS, JAK2, KIT
228.8CBL, HRAS, JAK2, KRAS
238.8CBL, HRAS, JAK2, KRAS
24
Show member pathways
8.8CBL, HRAS, KRAS, NRAS
25
Show member pathways
8.8CBL, HRAS, KRAS, NRAS
268.8CBL, HRAS, KRAS, NRAS
27
Show member pathways
8.8CBL, HRAS, KRAS, NRAS
28
Show member pathways
8.8CBL, HRAS, KRAS, NRAS
29
Show member pathways
8.8FLT3, HRAS, KIT, KRAS, NRAS
308.8FLT3, HRAS, KIT, KRAS, NRAS
31
Show member pathways
8.5CBL, FLT3, HRAS, KRAS, NRAS
328.5CSF1R, CSF3, FLT3, KIT
33
Show member pathways
8.5CBL, HRAS, KRAS, NRAS, RUNX1
34
Show member pathways
8.5CSF1R, HRAS, KIT, KRAS, NRAS
35
Show member pathways
8.4CBL, HRAS, JAK2, KRAS, NRAS
368.4CBL, HRAS, JAK2, KRAS, NRAS
37
Show member pathways
8.4CBL, HRAS, JAK2, KRAS, NRAS
38
Show member pathways
8.4CBL, HRAS, JAK2, KRAS, NRAS
39
Show member pathways
8.2CBL, HRAS, JAK2, KIT, KRAS, NRAS
40
Show member pathways
8.2CBL, FLT3, HRAS, JAK2, KRAS, NRAS
41
Show member pathways
8.1CSF1R, HRAS, JAK2, KIT, KRAS, NRAS
42
Show member pathways
8.0CBL, FLT3, HRAS, KIT, KRAS, NRAS
437.3CBL, CSF1R, FLT3, HRAS, KIT, KRAS
447.3CSF1R, CSF3, HRAS, JAK2, KIT, KRAS
45
Show member pathways
7.3CSF1R, CSF3, HRAS, JAK2, KIT, KRAS
46
Show member pathways
7.1CBL, CSF1R, FLT3, HRAS, KIT, KRAS
47
Show member pathways
7.0CSF1R, CSF3, FLT3, HRAS, JAK2, KIT
48
Show member pathways
7.0CSF1R, CSF3, FLT3, HRAS, JAK2, KIT
49
Show member pathways
6.5CBL, CSF1R, CSF3, FLT3, HRAS, JAK2
50
Show member pathways
6.5CBL, CSF1R, CSF3, FLT3, HRAS, JAK2

GO Terms for genes affiliated with Core Binding Factor Acute Myeloid Leukemia

About this section

Biological processes related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 28)
idNameGO IDScoreTop Affiliating Genes
1myeloid progenitor cell differentiationGO:000231810.6FLT3, KIT
2positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252310.5JAK2, KIT
3positive regulation of tyrosine phosphorylation of Stat3 proteinGO:004251710.5JAK2, KIT
4T cell differentiationGO:003021710.5KIT, RUNX2
5stem cell differentiationGO:004886310.5KIT, RUNX2
6positive regulation of phosphatidylinositol 3-kinase activityGO:004355210.4FLT3, KIT
7myeloid cell differentiationGO:003009910.3CBFB, RUNX1
8ossificationGO:000150310.0CBFB, RUNX1, RUNX2
9stimulatory C-type lectin receptor signaling pathwayGO:00022239.9HRAS, KRAS, NRAS
10positive regulation of actin cytoskeleton reorganizationGO:20002519.9CSF3, HRAS
11ERBB2 signaling pathwayGO:00381289.9HRAS, KRAS, NRAS
12cellular response to cytokine stimulusGO:00713459.6CSF1R, CSF3
13regulation of long-term neuronal synaptic plasticityGO:00481699.6HRAS, KRAS
14leukocyte migrationGO:00509009.5HRAS, KRAS, NRAS
15protein autophosphorylationGO:00467779.5CSF1R, FLT3, JAK2, KIT
16epidermal growth factor receptor signaling pathwayGO:00071739.4CBL, HRAS, JAK2, KRAS
17positive regulation of phosphatidylinositol 3-kinase signalingGO:00140689.3CSF3, FLT3, JAK2, KIT
18fibroblast growth factor receptor signaling pathwayGO:00085439.2HRAS, JAK2, KIT, KRAS, NRAS
19MAPK cascadeGO:00001659.1HRAS, JAK2, KIT, KRAS, NRAS
20activation of MAPKK activityGO:00001869.0HRAS, JAK2, KIT, KRAS, NRAS
21vascular endothelial growth factor receptor signaling pathwayGO:00480109.0HRAS, JAK2, KIT, KRAS, NRAS
22insulin receptor signaling pathwayGO:00082869.0HRAS, JAK2, KIT, KRAS, NRAS
23neurotrophin TRK receptor signaling pathwayGO:00480119.0HRAS, JAK2, KRAS, NRAS
24positive regulation of cell proliferationGO:00082848.7CSF3, FLT3, HRAS, RUNX2
25cytokine-mediated signaling pathwayGO:00192218.7CSF1R, CSF3, FLT3, JAK2, KIT
26axon guidanceGO:00074118.6CSF1R, HRAS, JAK2, KIT, KRAS
27innate immune responseGO:00450878.1CSF1R, HRAS, JAK2, KIT, KRAS, NRAS
28signal transductionGO:00071658.1CSF1R, HRAS, JAK2, KIT, NRAS

Molecular functions related to Core Binding Factor Acute Myeloid Leukemia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein tyrosine kinase activityGO:00047139.3CSF1R, FLT3, KIT

Sources for Core Binding Factor Acute Myeloid Leukemia

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet